| TITLE |
DATE |
| APP Pharmaceuticals Announces Approval and Launch of Clonidine Hydrochloride Injection |
11-Jul-2011 |
| APP Pharmaceuticals Announces Approval of Nafcillin For Injection, USP |
6-Jul-2011 |
| APP Pharmaceuticals Announces Approval Of Levothyroxine Sodium For Injection |
5-Jul-2011 |
| APP Pharmaceuticals Invests $38 Million to Expand Its Grand Island, New York Manufacturing Facility |
15-Jun-2011 |
| APP Pharmaceuticals Named NOVAPLUS® Pharmacy Manufacturer of the Year |
8-Jun-2011 |
| APP Pharmaceuticals to Market Letrozole Tablets, USP in the U.S. |
7-Jun-2011 |
| APP Pharmaceuticals Receives Approval for Piperacillin and Tazobactam for Injection |
1-Jun-2011 |
| APP Pharmaceuticals Announces Approval and Launch of Gemcitabine HCI for Injection, USP in 2 Gram Dosage Form |
19-May-2011 |
| App Pharmaceuticals Issues A Nationwide Voluntary Recall Of Irinotecan Hydrochloride Injection |
25-Mar-2011 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist
and Deregister Contingent Value Rights for APP Pharmaceuticals |
7-Mar-2011 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K
for APP Pharmaceuticals, Inc. (APP) |
23-Feb-2011 |
| APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to
Manufacture and Market Gemcitabine HCI for Injection |
26-Jan-2011 |
| APP Pharmaceuticals Announces Approval and Launch of Topotecan for Injection |
30-Nov-2010 |
| APP Pharmaceuticals to Launch Drug Hotline |
5-Nov-2010 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
1-Nov-2010 |
| APP Pharmaceuticals Announces Approval of Metoprolol Tartrate Injection, USP |
29-Oct-2010 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
2-Aug-2010 |
| APP Pharmaceuticals Announces Marketing Clearance of Preservative-Free Heparin Lock Flush Solution, USP |
6-Jul-2010 |
| APP Pharmaceuticals to Market Anastrozole Tablets in the U.S. |
29-Jun-2010 |
| APP Pharmaceuticals Announces Approval of Ganciclovir for Injection, USP |
22-Jun-2010 |
| APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP |
21-Jun-2010 |
| APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S. |
11-Jun-2010 |
| APP Pharmaceuticals Receives Approval for Lyophilized Oxaliplatin for Injection |
8-Jun-2010 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
3-May-2010 |
| Fresenius Kabi Enters Into Licensing and Settlement Agreements with sanofi-aventis |
1-Apr-2010 |
| APP Pharmaceuticals Receives Approval for Indomethacin for Injection |
23-Mar-2010 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-K |
23-Feb-2010 |
| Thomas H. Silberg to Retire as President and CEO of APP Pharmaceuticals, John Ducker Named as Successor |
2-Dec-2009 |
| Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc. |
2-Nov-2009 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
2-Nov-2009 |
| APP Pharmaceuticals Receives Approval for the First Generic Chlorothiazide Sodium for Injection, USP |
21-Oct-2009 |
| APP Pharmaceuticals Receives Approval for Sumatriptan Succinate Injection, USP |
8-Oct-2009 |
| APP Pharmaceutical Supports New USP Standards for Unfractionated Heparin |
1-Oct-2009 |
| APP Pharmaceuticals Receives Approval for Deferoxamine Mesylate for Injection, USP |
17-Sep-2009 |
| APP Pharmaceuticals Receives Approval for Penicillin G Potassium for Injection, USP |
25-Aug-2009 |
| APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection |
10-Aug-2009 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
3-Aug-2009 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q |
29-Apr-2009 |
| FRESENIUS KABI PHARMACEUTICALS HOLDING, INC,ANNOUNCES FILING OF FORM 10-K |
19-Feb-2009 |
| APP Pharmaceuticals Launches Rocuronium Bromide Injection |
20-Jan-2009 |
| APP Pharmaceuticals Launches Heparin-Focused Educational Web Site Called "Working Together For Patient Safety" |
5-Dec-2008 |
| Fresenius Kabi Pharmaceuticals Holding, Inc. Releases Third Quarter Results |
3-Nov-2008 |
| Fresenius SE Parent Company of Fresenius Kabi Pharmaceuticals Holding, Inc., Announces Date for Third Quarter Earnings |
31-Oct-2008 |
| APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius |
10-Sep-2008 |
| APP Pharmaceuticals Announces Completion of Acquisition by Fresenius |
10-Sep-2008 |
| APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal Trade Commission |
2-Sep-2008 |
| APP Pharmaceuticals Receives Manufacturing Approval for Three Product Codes of Heparin at Puerto Rico Facility |
18-Aug-2008 |
| APP Pharmaceuticals Reports 2008 Second Quarter Net Revenues of $198 Million, Operating Income of $53 Million |
31-Jul-2008 |
| APP Pharmaceuticals Announces Date for 2008 Second Quarter Financial Results and Investor Conference Call |
24-Jul-2008 |
| APP Pharmaceuticals to Be Acquired by Fresenius |
7-Jul-2008 |
| APP Pharmaceuticals Receives Final Approvals for Additional Dosages of Granisetron Hydrochloride Injection, USP |
3-Jul-2008 |
| APP Pharmaceuticals Launches Enhanced Labeling for Heparin Sodium Injection, USP |
2-Jun-2008 |
| APP Pharmaceuticals Provides Update on Issues Related to Heparin Crisis and Actions to Ensure Uninterrupted Safe Supply |
15-May-2008 |
| APP Pharmaceuticals Reports 2008 First Quarter Net Revenues of $148 Million, Gross Profit of $70 Million |
8-May-2008 |
| APP Pharmaceuticals Announces Date for 2008 First Quarter Financial Results and Investor Conference Call |
1-May-2008 |
| APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer |
30-Apr-2008 |
| APP Pharmaceuticals Receives FDA Approval for Colistimethate For Injection, USP |
21-Apr-2008 |
| APP Pharmaceuticals Launches Cefepime Hydrochloride for Injection |
25-Mar-2008 |
| APP Pharmaceuticals Reports Record Net Revenues of $647 Million and Gross Profit of $315 Million from Continuing Operations in 2007 |
7-Mar-2008 |
| APP Pharmaceuticals Announces Date for Fourth Quarter and Full-Year Financial Results and Investor Conference Call |
28-Feb-2008 |
| APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection |
27-Feb-2008 |
| APP Pharmaceuticals Announces Plan to Respond to Potential Therapeutic Heparin Shortage in the United States |
19-Feb-2008 |
| APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP |
8-Feb-2008 |
| APP Pharmaceuticals Receives FDA Approval for Caffeine Citrate Oral Solution, USP |
8-Feb-2008 |
| APP Pharmaceuticals Receives FDA Approval for Polymyxin B Sulfate for Injection, USP |
17-Jan-2008 |
| APP Pharmaceuticals Launches Granisetron Hydrochloride Injection, USP |
17-Jan-2008 |
| APP Pharmaceuticals Receives Letter Regarding Nasdaq Rule 4350 |
18-Dec-2007 |
| APP Pharmaceuticals Announces Successful Separation of its Business |
14-Nov-2007 |
| APP Pharmaceuticals to Present at Credit Suisse Healthcare Conference |
12-Nov-2007 |
| Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer |
18-Oct-2007 |
| APP Receives FDA Approval for Epirubicin HCl Injection |
17-Oct-2007 |
| APP Receives Two FDA Approvals for Fludarabine Phosphate |
16-Oct-2007 |
| Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer |
15-Oct-2007 |
| APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials |
5-Oct-2007 |
| APP Receives Tentative Approval for Granisetron Hydrochloride Injection, USP |
11-Sep-2007 |
| Abraxis BioScience to Present at the Bear Stearns Healthcare Conference |
4-Sep-2007 |
| Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer |
21-Aug-2007 |
| APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection |
10-Aug-2007 |
| Abraxis BioScience Files Information Statement in Connection with Its Announced Separation into Two Publicly Traded Companies |
9-Aug-2007 |
| Abraxis BioScience Reports Second Quarter 2007 Revenue of $243 Million versus $161 Million in Prior Year Period |
9-Aug-2007 |
| Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India |
8-Aug-2007 |
| Abraxis BioScience Launches Doxorubicin Hydrochloride Injection, USP |
8-Aug-2007 |
| Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial |
7-Aug-2007 |
| Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP |
6-Aug-2007 |
| Abraxis BioScience Acquires from the Buck Institute Exclusive Worldwide Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates |
6-Aug-2007 |
| Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL |
2-Aug-2007 |
| Abraxis BioScience Acquires Manufacturing Facility from Watson |
31-Jul-2007 |
| Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development of New Nanobiotechnologies |
26-Jul-2007 |
| Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union |
19-Jul-2007 |
| Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call |
16-Jul-2007 |
| Abraxis BioScience Announces Plan to Separate Into Two Independent Public Companies |
2-Jul-2007 |
| Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer from the University of Southern California |
19-Jun-2007 |
| Abraxis BioScience to Present at the Goldman Sachs 28th Annual Global Healthcare Conference |
7-Jun-2007 |
| ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer |
2-Jun-2007 |
| New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO |
30-May-2007 |
| Abraxis BioScience to Present at the Bank of America 2007 Health Care Conference |
23-May-2007 |
| Abraxis BioScience Founder Awarded Ellis Island Medal of Honor |
14-May-2007 |
| Abraxis BioScience Receives FDA Approvals for Clindamycin Injection, USP |
10-May-2007 |
| Abraxis BioScience Reports First Quarter 2007 Revenue of $212.2 Million Versus $144.5 Million in Prior Year Period |
10-May-2007 |
| Abraxis BioScience Announces Joint Venture With Cenomed for the Development of Novel Therapeutics for Neurological Diseases |
7-May-2007 |
| Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP |
19-Apr-2007 |
| Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab(TM)) Technology Platform in Targeting the Pathway |
19-Apr-2007 |
| Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway |
19-Apr-2007 |
| Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (ABRAXANE(R)) with Anti-Angiogenic Agents to Increase Tumor Response |
19-Apr-2007 |
| Abraxis BioScience Announces Date for First Quarter Financial Results and Investor Conference Call |
12-Apr-2007 |
| Abraxis BioScience to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference |
4-Apr-2007 |
| Abraxis BioScience to Initiate Two Phase I/II Clinical Trials with nab-docetaxel in Hormone Refractory Prostate and Metastatic Breast Cancer |
20-Mar-2007 |
| Abraxis BioScience Reports Record Revenue of $765 Million in 2006 Versus $521 Million for 2005 |
26-Feb-2007 |
| Abraxis Bioscience Completes Acquisition of Manufacturing Complex from Pfizer |
14-Feb-2007 |
| Abraxis BioScience Announces Date for Fourth Quarter and Full Year Financial Results and Investor Conference Call |
6-Feb-2007 |
| Abraxis BioScience to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
29-Jan-2007 |
| Abraxis BioScience to Present at the Wachovia Small and Mid-Cap Healthcare Conference |
22-Jan-2007 |
| Abraxis BioScience Files Marketing Application for ABRAXANE in Australia |
16-Jan-2007 |
| Abraxis BioScience to Present at the JPMorgan Healthcare Conference |
4-Jan-2007 |
| Abraxis BioScience Launches Ondansetron Injection, USP |
3-Jan-2007 |
| Interim Data from a Randomized, Head-to-Head Phase II Study Shows Weekly ABRAXANE Increased Tumor Response Rate by Greater Than 60 Percent versus Taxotere in First-Line Treatment of Metastatic Breast Cancer |
17-Dec-2006 |
| Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium |
11-Dec-2006 |
| Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP |
28-Nov-2006 |
| Abraxis BioScience to Present at the Lazard Capital Markets Life Sciences Conference |
20-Nov-2006 |
| Abraxis BioScience Reports Third Quarter 2006 Adjusted Earnings Per Share of $0.21 versus $0.06 in the Prior Year Period, Excluding Merger-Related Items and Stock Compensation Expense |
6-Nov-2006 |
| Abraxis BioScience Launches New Abraxane Patient Assistance Program |
30-Oct-2006 |
| Abraxis BioScience to Present at the CIBC World Markets Annual Healthcare Conference |
18-Oct-2006 |
| Abraxis BioScience Announces Date for Third Quarter Financial Results and Investor Conference Call |
17-Oct-2006 |
| Abraxis BioScience Files Marketing Application with the European Medicines Agency for ABRAXANE in the Treatment of Breast Cancer |
28-Sep-2006 |
| Abraxis BioScience to Present at the UBS Global Life Sciences Conference |
20-Sep-2006 |
| Abraxis BioScience Names Leadership Team for Its Abraxis Pharmaceutical Products Division; Appointment of President and Chief Operating Officer of APP Solidifies Management Structure of Hospital-Based Division |
8-Sep-2006 |
| Abraxis Provides Update on Oncologic Drugs Advisory Committee Recommendation Regarding ABRAXANE Trial Design for Adjuvant Therapy for Node-Positive Breast Cancer |
7-Sep-2006 |
| Abraxis BioScience Reports Second Quarter 2006 Adjusted Earnings Per Share, Excluding Merger-Related Items and Stock Compensation Expense, of $0.17 versus $0.06 in the Prior Year |
3-Aug-2006 |
| Abraxis BioScience Announces Results from Its Annual Meeting of Stockholders |
2-Aug-2006 |
| Abraxis BioScience Appoints Lisa Gopala as Chief Financial Officer |
2-Aug-2006 |
| Abraxis BioScience Receives Milestone Payment from Taiho Pharmaceutical Co. for the Initiation of the First Clinical Trial for ABRAXANE in Japan |
13-Jul-2006 |
| Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call |
6-Jul-2006 |
| Abraxis BioScience Completes Acquisition of the AstraZeneca U.S. Branded Anesthetic and Analgesic Product Lines |
28-Jun-2006 |
| Abraxis BioScience to Host R&D Investor Day; Company to Provide In-depth Overview of Extensive Pipeline and Platform Technologies |
15-Jun-2006 |
| Abraxis BioScience Receives Approval in Canada for ABRAXANE to Treat Metastatic Breast Cancer Including First-Line Disease |
7-Jun-2006 |
| Abraxis BioScience to Present at the Goldman Sachs Global Healthcare Conference |
5-Jun-2006 |
| Three Studies Confirm Activity of ABRAXANE As First-Line Treatment in Non-Small Cell Lung Cancer and Show Higher Tumor Response Rates Than Current Standard of Care |
4-Jun-2006 |
| Abraxis BioScience Appoints New Officers to Executive Management Team |
25-May-2006 |
| Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives |
25-May-2006 |
| Abraxis BioScience Adds Research Facility and Sets in Motion the Development of a Biopharmaceutical Campus |
18-May-2006 |
| Abraxis BioScience to Present at the Bank of America 2006 Health Care Conference |
11-May-2006 |
| Abraxis BioScience Reports Record First Quarter 2006 Adjusted Earnings Per Share, Excluding Primarily Stock Option Expense, of $0.41, an Increase of 21 Percent; Net Sales Increase 19 Percent to $143.8 Million |
28-Apr-2006 |
| Abraxis BioScience Announces Co-Promotion Agreement with AstraZeneca for ABRAXANE(R) in the U.S. and the Acquisition of AstraZeneca's U.S. Branded Anesthetic and Analgesic Product Lines |
27-Apr-2006 |
| Abraxis BioScience to Acquire European and U.S. Compliant Manufacturing Complex from Pfizer |
25-Apr-2006 |
| Abraxis BioScience to Present at the UBS Global Specialty Pharmaceutical Conference |
20-Apr-2006 |
| Abraxis BioScience Announces Date for First Quarter Financial Results and Investor Conference Call |
19-Apr-2006 |
| American Pharmaceutical Partners and American BioScience Complete Merger to Form Abraxis BioScience |
18-Apr-2006 |
| American Pharmaceutical Partners Adds to Its Broad Oncology Portfolio with the Approval of Mitoxantrone Injection, USP |
11-Apr-2006 |
| American Bioscience and American Pharmaceutical Partners to Present Six Abstracts on Applications of Nanoparticle Albumin Bound (nab(TM)) Tumor Targeting Technology at the 97th American Association of Cancer Research Annual Meeting |
4-Apr-2006 |
| Abraxis Oncology Names Joseph Hogan Vice President of U.S. Sales and Marketing |
20-Mar-2006 |
| American Pharmaceutical Partners Receives Two Tentative FDA Approvals for Ondansetron Injection, USP |
9-Mar-2006 |
| American Pharmaceutical Partners Reports Record 2005 Sales and Net Income |
17-Feb-2006 |
| American Pharmaceutical Partners Receives FDA Approval for Carboplatin Injection, 600 mg |
17-Feb-2006 |
| American Pharmaceutical Partners Receives Two FDA Approvals for Ceftriaxone for Injection, USP, Maintaining Company's Leadership Position in the Cephalosporin Market |
16-Feb-2006 |
| American Pharmaceutical Partners and American BioScience Announce Senior Management Team of Abraxis BioScience |
14-Feb-2006 |
| American Pharmaceutical Partners Receives Two FDA Approvals for Octreotide Acetate Injection |
13-Feb-2006 |
| American Pharmaceutical Partners Reiterates 2005 ABRAXANE Revenue Guidance; Schedules Fourth Quarter and Full Year Earnings Release and Conference Call |
9-Feb-2006 |
| American Pharmaceutical Partners to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 8 |
2-Feb-2006 |
| Patrick Soon-Shiong, M.D., CEO of American BioScience and Larry Norton, M.D., of Memorial Sloan Kettering Receive Gilda's Club New York City Award for the Advancement of Cancer Medicine |
27-Jan-2006 |
| Carlo Montagner to Be Named President of Abraxis Oncology Upon Completion of Merger of APP and ABI |
25-Jan-2006 |
| American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as Global Vice President Sales and Marketing - Abraxis Oncology |
21-Dec-2005 |
| Sir Richard Sykes, Former Glaxo Wellcome Chairman, CEO and GlaxoSmithKline Chairman, Agrees to Join the Abraxis BioScience Board of Directors |
20-Dec-2005 |
| American Pharmaceutical Partners and Technoflex Announce Joint Venture to Establish Sterile Bag-Fill Capability for Injectable Drugs in the U.S. |
15-Dec-2005 |
| American Pharmaceutical Partners Receives FDA Approval for Azithromycin for Injection |
14-Dec-2005 |
| Positive ABRAXANE(R) Data in Early-Stage (Adjuvant) Breast Cancer and Solid Tumors Reported at San Antonio Breast Cancer Symposium |
9-Dec-2005 |
| American Pharmaceutical Partners Receives FDA Approval for Ampicillin and Sulbactam for Injection, USP |
30-Nov-2005 |
| American Pharmaceutical Partners to Merge with Parent Company, American Bioscience, Creating Abraxis Bioscience, a Fully-Integrated Biopharmaceutical Company with Global Ownership of ABRAXANE(R), nab(TM) Platform and Deep Pipeline |
28-Nov-2005 |
| American Pharmaceutical Partners to Present at the Lazard Capital Markets Life Sciences Conference on November 30 |
23-Nov-2005 |
| American BioScience Licenses ABRAXANE(TM) to Taiho Pharmaceutical Co., Ltd., One of the Largest Oncology Companies in Japan |
16-Nov-2005 |
| Key to Improved Chemotherapy Response to ABRAXANE(TM) Validated by Clinical Data |
3-Nov-2005 |
| American Pharmaceutical Partners to Present at the CIBC 16th Annual Healthcare Conference on November 8 |
2-Nov-2005 |
| American Pharmaceutical Partners Announces Record Quarterly Sales of $128.8 Million |
1-Nov-2005 |
| Journal of Clinical Oncology Publishes Pivotal Phase III Study Reporting Superior Response Rate of ABRAXANE(TM) Compared With Taxol(R) in Women With Metastatic Breast Cancer(1) |
1-Nov-2005 |
| Phase I Study of High Dose Weekly ABRAXANE(TM) Published in Journal of Clinical Oncology: Responses Achieved in Patients With Taxol(R) Refractory Ovarian Cancer and Lung Cancer |
1-Nov-2005 |
| American Pharmaceutical Partners to Report 2005 Third Quarter Financial Results and Host Conference Call on November 1, 2005 |
20-Oct-2005 |
| American Pharmaceutical Partners Provides Update on Its Melrose Park, IL Manufacturing Operations |
26-Sep-2005 |
| American Pharmaceutical Partners to Present at The Bear Stearns 18th Annual Healthcare Conference on September 12 |
6-Sep-2005 |
| American Pharmaceutical Partners Launches Enhanced Corporate Web Site |
30-Aug-2005 |
| American Pharmaceutical Partners Reports on Melrose Park, Il Operations and Provides Update on $120 Million Company-Wide Facility Upgrade and Expansion Initiative |
25-Aug-2005 |
| American Pharmaceutical Partners Reports on Status of Ceftriaxone Product Approval |
28-Jul-2005 |
| American Pharmaceutical Partners Reports All-Time Record Sales of $124.5 Million, Record Second Quarter Earnings of $0.28 Per Share |
22-Jul-2005 |
| American Pharmaceutical Partners to Report 2005 Second Quarter Financial Results and Host Conference Call on July 22, 2005 |
7-Jul-2005 |
| New Drug Submission for ABRAXANE(TM) Filed in Canada for Metastatic Breast Cancer |
15-Jun-2005 |
| American Pharmaceutical Partners to Present at the Banc of America Securities Healthcare Conference 2005 on May 17 |
10-May-2005 |
| American Pharmaceutical Partners Reports Record First Quarter Sales With All Time Record Gross Margin, Quarterly Earnings and EPS |
4-May-2005 |
| American Pharmaceutical Partners and American Bioscience Announce Completion of Patient Accrual for Dose Dense ABRAXANE(TM) Study in Adjuvant Breast Cancer |
3-May-2005 |
| American Pharmaceutical Partners Launches Esmolol Hydrochloride Injection |
2-May-2005 |
| American Pharmaceutical Partners Receives Approval for Adenosine |
29-Apr-2005 |
| American Pharmaceutical Partners Receives Approval for Dexamethasone Sodium Phosphate |
25-Apr-2005 |
| American Pharmaceutical Partners Names New General Counsel |
25-Apr-2005 |
| American Pharmaceutical Partners Receives Approval for Vinorelbine Tartrate |
19-Apr-2005 |
| American Pharmaceutical Partners to Report 2005 First Quarter Financial Results and Host Conference Call on May 4, 2005 |
18-Apr-2005 |
| American BioScience Presents Data on Oncolytic Applications of Its Nanoparticle Albumin Bound (nab(TM)) Technology Platform at the 96th American Association for Cancer Research Annual Meeting |
18-Apr-2005 |
| American BioScience Presents Clinical Trial Results of the First Human Study of Coroxane(TM) for the Treatment of Restenosis at the Cardiovascular Revascularization Therapies (CRT) Conference |
5-Apr-2005 |
| American Pharmaceutical Partners Announces Initiation of a Clinical Study of Abraxane in the Most Widely Used Combination Chemotherapy Regimen of Paclitaxel and Herceptin in HER2-Positive Breast Cancer Patients |
4-Apr-2005 |
| American Pharmaceutical Partners to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference On April 5 |
24-Mar-2005 |
| American Pharmaceutical Partners Announces Presentation of ABRAXANE(TM) Survival Data at 22nd Annual Miami Breast Cancer Conference |
25-Feb-2005 |
| American Pharmaceutical Partners Reports Record Quarterly Sales and Earnings; Net Sales Increase 37% to $123 Million, Net Income of $0.30 Per Share |
16-Feb-2005 |
| American Pharmaceutical Partners to Report 2004 Fourth Quarter and Full Year Financial Results and Host Conference Call on February 16, 2005 |
1-Feb-2005 |
| American Pharmaceutical Partners Announces Launch Date Of ABRAXANE(TM) for Metastatic Breast Cancer |
25-Jan-2005 |
| FDA Approves ABRAXANE(TM), First in New Class of Protein-Bound Particle Drugs, for Metastatic Breast Cancer |
7-Jan-2005 |
| American Pharmaceutical Partners Presents Data on High Dose Weekly ABRAXANE(TM) in Taxane-Refractory Metastatic Breast Cancer Patients |
13-Dec-2004 |
| American Pharmaceutical Partners Announces Upcoming Presentations at the 27th Annual San Antonio Breast Cancer Symposium |
6-Dec-2004 |
| American Pharmaceutical Partners to Present at Lazard Life Sciences Conference on December 1 |
24-Nov-2004 |
| American Pharmaceutical Partners' Founder Announces Appointment of Pharma Industry Veteran Alan Heller as President and CEO; Soon-Shiong Assumes New Role as Executive Chairman Focusing Efforts on Strategic Initiatives and Proprietary Next-Generation Produ |
18-Nov-2004 |
| American Pharmaceutical Partners to Present at CIBC World Markets 15th Annual Healthcare Conference on November 10 |
1-Nov-2004 |
| American Pharmaceutical Partners Receives Approval for Amiodarone Hydrochloride |
27-Oct-2004 |
| American Pharmaceutical Partners Receives Approval for Carboplatin Injection |
21-Oct-2004 |
| American Pharmaceutical Partners Reports Net Sales of $96 Million in 2004 Third Quarter With Gross Margin of 54% |
21-Oct-2004 |
| American Pharmaceutical Partners Launches Carboplatin for Injection, USP |
18-Oct-2004 |
| American Pharmaceutical Partners to Report 2004 Third Quarter Financial Results and Host Conference Call on October 21, 2004 |
15-Oct-2004 |
| American Pharmaceutical Partners Receives FDA Approval for Flumazenil Injection |
13-Oct-2004 |
| American Pharmaceutical Partners to Webcast Investor Day on October 8 |
5-Oct-2004 |
| American Pharmaceutical Partners Announces Addition of Three Seasoned Senior Executives to Management Team |
4-Oct-2004 |
| American Pharmaceutical Partners Obtains an Unsecured $100 Million Credit Facility |
7-Sep-2004 |
| American Pharmaceutical Partners Receives Tenth Product Approval of 2004 With Methylprednisolone Sodium Succinate for Injection USP |
2-Aug-2004 |
| American Pharmaceutical Partners Establishes Operations in Europe Through Acquisition of Manufacturing Facility and Oncology Products From Bigmar, Inc. |
28-Jul-2004 |
| American Pharmaceutical Partners Reports Record Net Sales of $98 Million in 2004 Second Quarter With Gross Margin of 54% |
22-Jul-2004 |
| American Pharmaceutical Partners Receives Tentative Approval for Esmolol Hydrochloride Injection |
21-Jul-2004 |
| American Pharmaceutical Partners Receives FDA Approval for 40g Vial of Piperacillin for Injection, USP |
16-Jul-2004 |
| American Pharmaceutical Partners Launches Tobramycin Powder Marking Company's First 505(b)(2) NDA Approval |
15-Jul-2004 |
| American Pharmaceutical Partners to Report 2004 Second Quarter Financial Results and Host Conference Call on July 22, 2004 |
8-Jul-2004 |
| American Pharmaceutical Partners Receives FDA Approval for Dimenhydrinate Injection, USP |
24-Jun-2004 |
| American Pharmaceutical Partners Reports Tolerability of High Dose ABRAXANE(TM) Administered Weekly in Patients With Advanced Cancers |
8-Jun-2004 |
| American Pharmaceutical Partners Reports That Weekly Administration of ABRAXANE(TM) is Active in Patients Who Had Failed Treatment for Breast Cancer With TAXOL or Taxotere Therapy |
7-Jun-2004 |
| American Pharmaceutical Partners Provides Schedule for Abraxane-Related Presentations at Upcoming ASCO Annual Meeting |
3-Jun-2004 |
| American Pharmaceutical Partners Receives FDA Approval for Terbutaline Sulfate Injection |
28-May-2004 |
| American Pharmaceutical Partners and American BioScience Announce FDA Acceptance of New Drug Application of ABRAXANE(TM) for the Treatment of Metastatic Breast Cancer |
10-May-2004 |
| American Pharmaceutical Partners to Present at Banc of America's 2004 Healthcare Conference on May 21 |
5-May-2004 |
| American Pharmaceutical Partners Receives FDA Approval for Cladribine Injection |
27-Apr-2004 |
| American Pharmaceutical Partners Reports First Quarter Net Sales of $89 Million and EPS of $0.16 |
21-Apr-2004 |
| American Pharmaceutical Partners to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on April 27 |
13-Apr-2004 |
| American Pharmaceutical Partners to Report 2004 First Quarter Financial Results and Host Conference Call on April 21, 2004 |
12-Apr-2004 |
| American Pharmaceutical Partners and American BioScience Announce Filing of a New Drug Application for FDA Approval of ABRAXANE(TM) for the Treatment of Metastatic Breast Cancer |
8-Mar-2004 |
| American Pharmaceutical Partners Reports Full Year 2003 Net Sales of $351 Million With Net Income Growth of 59% to $72 Million and EPS of $0.99 |
26-Feb-2004 |
| American Pharmaceutical Partners Receives Tentative Approval for Anti-Infective Ciprofloxacin |
24-Feb-2004 |
| American Pharmaceutical Partners Receives Canadian Marketing Approvals for Piperacillin for Injection and Fluconazole Injection |
24-Feb-2004 |
| American Pharmaceutical Partners to Report 2003 Fourth Quarter and Year End Financial Results and Host Conference Call on February 26 |
5-Feb-2004 |
| American Pharmaceutical Partners to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5 |
29-Jan-2004 |
| American Pharmaceutical Partners Receives Manufacturer Excellence Award From Cardinal Health |
29-Jan-2004 |
| American Pharmaceutical Partners Receives FDA Approval for Liquid Form of Cytarabine Injection |
20-Jan-2004 |
| American Pharmaceutical Partners Appoints Executive Director of Medical Affairs |
15-Dec-2003 |
| American Pharmaceutical Partners Receives FDA Approval for Piperacillin Injection |
8-Dec-2003 |
| Telephonic Replay and Webcast Available From Clinical Investigator Presentation of ABRAXANE(TM) Phase III Data Released at San Antonio Breast Cancer Symposium |
8-Dec-2003 |
| Detailed Positive ABRAXANE(TM) Phase III Data Released at San Antonio Breast Cancer Symposium: Patients With Metastatic Breast Cancer Treated With ABRAXANE(TM) Achieve Almost Double the Tumor Response Rate and Longer Time to Tumor Progression Compared Wit |
5-Dec-2003 |
| American Pharmaceutical Partners Receives FDA Approval For Piperacillin Injection |
17-Nov-2003 |
| American Pharmaceutical Partners to Present at CIBC World Markets 14th Annual Healthcare Conference on November 12 |
4-Nov-2003 |
| American Pharmaceutical Partners States Lawsuit Filed by Plaintiff Law Firm Is Baseless and Without Merit |
26-Oct-2003 |
| American Pharmaceutical Partners Reports 2003 Third Quarter Net Sales of $90.4 Million, 73% Net Income Growth and EPS Of $0.25 |
23-Oct-2003 |
| American Pharmaceutical Partners Announces Acceptance of ABRAXANE(TM) Data as Late-Breakers Both at the Chemotherapy Foundation Symposium and at the San Antonio Breast Cancer Conference |
20-Oct-2003 |
| American Pharmaceutical Partners to Report 2003 Third Quarter Financial Results and Host Conference Call on October 23 |
15-Oct-2003 |
| American Pharmaceutical Partners Provides Update on Upcoming Events |
7-Oct-2003 |
| Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer: Patients on ABRAXANE Achieve Higher Tumor Response Rate and Longer Time to Tumor Progression Compared to TAXOL(R) |
24-Sep-2003 |
| American Pharmaceutical Partners Announces Brand Name for ABI-007 And Appointment of National Sales Director |
19-Sep-2003 |
| American Pharmaceutical Partners to Present at UBS Warburg Global Life Sciences Conference on September 25 |
15-Sep-2003 |
| American Pharmaceutical Partners Announces Issuance of Patent Covering Formulations and Methods of Use of Cremophor-Free Taxanes |
8-Sep-2003 |
| American Pharmaceutical Partners Files Shelf Registration Statement |
5-Sep-2003 |
| American Pharmaceutical Partners Announces 3 for 2 Stock Split in Form of a Stock Dividend |
8-Aug-2003 |
| American Pharmaceutical Partners Recruits Seasoned Executive Marketing Team in Preparation for ABI-007 Launch |
1-Aug-2003 |
| American Pharmaceutical Partners Reports Record 2003 Second Quarter Results; Net Sales of $90.4 Million and EPS of $0.41 |
24-Jul-2003 |
| American Pharmaceutical Partners Acquires Canadian Market Rights to Five Injectable Products From Eli Lilly Canada Inc. |
16-Jul-2003 |
| American Pharmaceutical Partners To Report 2003 Second Quarter Financial Results and Host Conference Call on July 24 |
9-Jul-2003 |
| American Pharmaceutical Partners Receives ANDA Approval For Valproate Sodium Injection |
30-Jun-2003 |
| American Pharmaceutical Partners Announces Positive Results of Intra-Arterial ABI-007 in Phase II Trial in Head and Neck Cancer Patients and in Patients With Cancers of the Pelvis |
3-Jun-2003 |
| American Pharmaceutical Partners 100% Compliant With Proposed FDA Guidelines On Bar Coding |
2-Jun-2003 |
| American Pharmaceutical Partners Announces Anti-Tumor Activity of ABI-007 In Breast Cancer Patients Resistant to Taxane Therapy |
2-Jun-2003 |
| American Pharmaceutical Partners Announces the Launch of Five Products In Canada |
29-May-2003 |
| American Pharmaceutical Partners to Present at Upcoming 2003 ASCO Annual Meeting and UBS Warburg Global Specialty Pharmaceutical Conference |
29-May-2003 |
| American Pharmaceutical Partners to Present at UBS Warburg Global Specialty Pharmaceutical Conference on June 4 |
27-May-2003 |
| American Pharmaceutical Partners Announces Positive Results in ABI-007 Clinical Studies to be Presented at the 2003 ASCO Annual Meeting |
19-May-2003 |
| American Pharmaceutical Partners Launches Calcitriol |
6-May-2003 |
| American Pharmaceutical Partners Announces Extension of Stock Repurchase Program |
29-Apr-2003 |
| American Pharmaceutical Partners to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on April 30 |
25-Apr-2003 |
| American Pharmaceutical Partners Reports Strong 2003 First Quarter Results |
24-Apr-2003 |
| American Pharmaceutical Partners Receives Two ANDA Approvals |
22-Apr-2003 |
| American Pharmaceutical Partners to Report 2003 First Quarter Financial Results and Host Conference Call on April 24 |
15-Apr-2003 |
| American Pharmaceutical Partners to Present at Banc of America's 2003 Healthcare Conference on March 25 |
18-Mar-2003 |
| American Pharmaceutical Partners 2003 Annual Meeting of Stockholders To Be Held on April 24 |
12-Mar-2003 |
| American Pharmaceutical Partners Posts 258% Growth in 2002 Net Earnings, $0.90 Per Share |
26-Feb-2003 |
| American Pharmaceutical Partners, Inc. Announces 2002 Fourth Quarter and Full Year Financial Results Conference Call; Wednesday, February 26, 2003, at 8:30 a.m. PT, 11:30 a.m. ET |
20-Feb-2003 |
| American Pharmaceutical Partners Reports Anticipated Launch Dates for Various Dosage Forms of Vincristine |
30-Jan-2003 |
| American Pharmaceutical Partners to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5 |
29-Jan-2003 |
| American Pharmaceutical Partners Receives Second Product Approval in 2003 |
29-Jan-2003 |
| American Pharmaceutical Partners Raises 2002 Fourth Quarter and Full Year Earnings Guidance |
21-Jan-2003 |
| American Pharmaceutical Partners Announces FDA Grants Fast Track Designation for ABI-007 for Metastatic Breast Cancer |
17-Jan-2003 |
| American Pharmaceutical Partners Receives FDA Approval and 180 Days of Marketing Exclusivity for Calcitriol |
13-Jan-2003 |
| American Pharmaceutical Partners Achieves Record Number of ANDA Approvals in 2002 |
20-Dec-2002 |
| American Pharmaceutical Partners Receives Two ANDA Approvals And Adopts Further Stock Repurchase Program |
10-Dec-2002 |
| American Pharmaceutical Partners Product Innovation: Announces Launch of Novel Devices to Minimize Medication Dispensing Errors |
9-Dec-2002 |
| American Pharmaceutical Partners Leads Industry With Patient Safety-Enhancement Commitment To Barcoding |
6-Dec-2002 |
| American Pharmaceutical Partners Announces Completion of Patient Enrollment for Pivotal Phase III Trial of ABI-007 for Metastatic Breast Cancer |
3-Dec-2002 |
| American Pharmaceutical Partners Receives Multiple Contract Awards for Amiodarone |
20-Nov-2002 |
| American Pharmaceutical Partners Receives Approval For Ifosfamide in Canada |
31-Oct-2002 |
| American Pharmaceutical Partners to Present at CIBC World Markets Thirteenth Annual Health Care Conference on November 5 |
31-Oct-2002 |
| American Pharmaceutical Partners Reports Record Third Quarter Revenues and Net Income, Posts Earnings of $0.21 Per Share |
25-Oct-2002 |
| American Pharmaceutical Partners Announces Report From Data Monitoring Committee Regarding ABI-007 Phase III Trial |
25-Oct-2002 |
| American Pharmaceutical Partners Launches Amiodarone Hydrochloride in Liquid Form |
17-Oct-2002 |
| American Pharmaceutical Partners, Inc. Announces 2002 Third Quarter Financial Results Conference Call; Friday, October 25, 2002, at 8:00 a.m. PT, 11:00 a.m. ET |
16-Oct-2002 |
| Drug Maker's Focus: Improved Breast Cancer Treatment |
9-Oct-2002 |
| American Pharmaceutical Partners Launches Ifosfamide; Receives Multiple Contract Awards |
3-Sep-2002 |
| American Pharmaceutical Partners Named One Of Fastest Growing Technology Companies |
26-Aug-2002 |
| American Pharmaceutical Partners Announces Addition To Management Team With Appointment of CFO |
12-Aug-2002 |
| American Pharmaceutical Partners Announces Stock Repurchase Program |
29-Jul-2002 |
| American Pharmaceutical Partners Posts Record Revenues And Net Income for 2002 Second Quarter |
25-Jul-2002 |
| American Pharmaceutical Partners, Inc. Announces 2002 Second Quarter Financial Results Conference Call; Thursday, July 25, 2002, at 8:30 a.m. PT, 11:30 a.m. ET |
16-Jul-2002 |
| American Pharmaceutical Partners Receives Approval for Ifosfamide For Injection, USP, With 180 Days of Marketing Exclusivity |
5-Jun-2002 |
| American Pharmaceutical Partners to Present at UBS Warburg Global Specialty Pharmaceuticals Conference on June 6 |
4-Jun-2002 |
| American Pharmaceutical Partners Receives Approval for Generic Benadryl(R) Injection |
3-Jun-2002 |
| American Pharmaceutical Partners Launches Milrinone Lactate Injection |
31-May-2002 |
| American Pharmaceutical Partners Receives Tentative Approval For Anti-Cancer Compound Carboplatin |
30-May-2002 |
| American Pharmaceutical Partners Launches Pamidronate Disodium in Liquid Form |
29-May-2002 |
| American Pharmaceutical Partners Presents Phase II Trial Results in Metastatic Breast Cancer for ABI-007, a Novel Protein-Engineered Nanoparticle Form Of Leading Cancer Agent Paclitaxel |
20-May-2002 |
| American Pharmaceutical Partners Presents Unique Nanotransporter Technology For Cancer Drug at Nanotech Planet Conference and Expo |
15-May-2002 |
| American Pharmaceutical Partners' Subsidiary Granted Patent For Liquid Pamidronate |
30-Apr-2002 |
| American Pharmaceutical Partners to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on May 1 |
29-Apr-2002 |
| American Pharmaceutical Partners Posts Strong Revenues, Net Income for 2002 First Quarter |
25-Apr-2002 |
| American Pharmaceutical Partners to Report 2002 First Quarter Financial Results and Host Conference Call on April 25 |
12-Apr-2002 |
| American Pharmaceutical Partners and SuperGen Join Forces To Market Anti-Cancer Compound Mitomycin |
11-Apr-2002 |
| American Pharmaceutical Partners Reports Highlight of Positive Data From Initial Studies of ABI-007, a Paclitaxel Nanoparticle, in TAXOL-Failure Patients at AACR Annual Meeting |
10-Apr-2002 |
| American Pharmaceutical Partners to Present At Banc of America Securities Healthcare Conference on April 3 |
1-Apr-2002 |
| American Pharmaceutical Partners Responds to Recent Story In The New York Times |
27-Mar-2002 |
| Amex to Trade Options on American Pharmaceutical, Inc. |
15-Mar-2002 |
| American Pharmaceutical Partners Posts Strong 2001 Fourth Quarter And Full Year Financial Results |
26-Feb-2002 |
 |
